About Cronos Group (CVE:MJN)
Cronos Group, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canadas Marihuana for Medical Purposes Regulations (MMPR). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group was incorporated in January, 2013 and is based in Toronto, Canada.
Industry, Sector and Symbol:
- Industry: Biotechnology
- Sub-Industry: Cannabis
- Sector: Healthcare
- Symbol: CVE:MJN
- CUSIP: N/A
- Web: thecronosgroup.com
- Trailing EPS: C$0.03
- Net Margins: 27.17%
- Return on Equity: 1.38%
- Return on Assets: 1.23%
- Outstanding Shares: 133,142,000
Frequently Asked Questions for Cronos Group (CVE:MJN)
What is Cronos Group's stock symbol?
Cronos Group trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MJN."
When will Cronos Group make its next earnings announcement?
Where is Cronos Group's stock going? Where will Cronos Group's stock price be in 2017?
2 brokers have issued 1 year price targets for Cronos Group's shares. Their predictions range from C$3.00 to C$3.00. On average, they expect Cronos Group's share price to reach C$3.00 in the next twelve months. View Analyst Ratings for Cronos Group.
Who are some of Cronos Group's key competitors?
Some companies that are related to Cronos Group include ProMetic Life Sciences (PLI), Sirtex Medical Limited (SRX), Theratechnologies (TH), Mirati Therapeutics (MRTX), OrganiGram Holdings (OGI), Siga Technologies (SIGA), VBI Vaccines (VBIV), Osiris Therapeutics (OSIR), XOMA Corporation (XOMA), Anavex Life Sciences Corp. (AVXL), Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), ContraFect Corporation (CFRX), Concordia International Corp (CXR), Soligenix (SNGX), Senesco Technologies (SVON), Mateon Therapeutics (MATN) and Windtree Therapeutics (WINT).
Who are Cronos Group's key executives?
Cronos Group's management team includes the folowing people:
- Michael Ryan Gorenstein, President, Chief Executive Officer, Vice Chairman of the Board, Corporate Secretary
- William Hilson, Chief Financial Officer
- Jason Adler, Director
- Ryan Roebuck, Director
- Alan Mark Friedman, Independent Director (Age 45)
- Michael Howard Krestell, Independent Director
How do I buy Cronos Group stock?
Shares of Cronos Group and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Cronos Group's stock price today?
One share of Cronos Group stock can currently be purchased for approximately C$3.91.
How big of a company is Cronos Group?
Cronos Group has a market capitalization of C$562.16 million.
How can I contact Cronos Group?
Cronos Group's mailing address is 76 Stafford St Suite 302, TORONTO, ON M6J 2S1, Canada. The company can be reached via phone at +1-416-5040004.
MarketBeat Community Rating for Cronos Group (CVE MJN)MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Cronos Group (CVE:MJN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||C$3.00|
Consensus Price Target History for Cronos Group (CVE:MJN)
Analysts' Ratings History for Cronos Group (CVE:MJN)
(Data available from 11/19/2015 forward)
|7/5/2017||Canaccord Genuity||Set Price Target||Speculative Buy||C$3.00|
|2/10/2017||Beacon Securities||Reiterated Rating||Buy|
Earnings History for Cronos Group (CVE:MJN)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Cronos Group (CVE:MJN)
2017 EPS Consensus Estimate: ($0.01)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Cronos Group (CVE:MJN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cronos Group (CVE MJN)
Insider Trades by Quarter for Cronos Group (CVE MJN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/7/2017||Michael Ryan Gorenstein||Director||Buy||5,000||C$2.24||C$11,200.00|
|9/7/2017||William Lawrence Hilson||Insider||Buy||11,000||C$2.25||C$24,750.00|
|6/15/2017||Michael Howard Krestell||Director||Sell||83,700||C$1.78||C$148,986.00|
|6/7/2017||Jason Marc Adler||Insider||Buy||5,000||C$1.77||C$8,850.00|
|6/6/2017||Jason Marc Adler||Insider||Buy||80,000||C$1.73||C$138,400.00|
|6/5/2017||William Lawrence Hilson||Insider||Buy||22,000||C$1.91||C$42,020.00|
|5/21/2015||Steven G Isenberg||Director||Buy||20,000||C$0.50||C$10,000.00|
|5/19/2015||Steven G Isenberg||Director||Buy||55,000||C$0.50||C$27,500.00|
Latest Headlines for Cronos Group (CVE MJN)
Financials are not available for this stock.
Cronos Group (CVE MJN) Chart for Sunday, November, 19, 2017